Franco Locatelli, MD, PhD, head of the Department of Pediatric Hematology and Oncology at IRCCS Bambino Gesu Children’s Hospital in Rome, discusses the treatment of both adult and pediatric patients with chronic graft versus host disease (cGvHD).
Monitoring the safety and efficacy of janus kinase (JAK) inhibitors is key when treating patients with chronic graft versus host disease (cGvHD), says Franco Locatelli, MD, PhD, head of the Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesu Children’s Hospital, Rome, and professor of pediatrics at the Sapienza, University of Rome, Italy.
Transcript
What are some important considerations researchers should take into account when testing drugs in pediatric populations with cGvHD?
It's important that the studies on drugs used to treat different complications be performed in the pediatric population. Number 1, to identify the recommended dose, and number 2, to validate the data that has been obtained in adults, and also to draw important information about the predictive prognostic factors in terms of both response and overall survival rate.
Are there any specific monitoring or follow-up recommendations for pediatric patients receiving treatment with JAK inhibitors?
No, at the moment, the safety profile, as I mentioned before, is comparable to that reported in the adult population. Infections occured in around three-quarters of the patients, and in particular, viral infections were diagnosed in 40% of the patients, including SARS-CoV-2 [COVID-19] infection. So, a careful viral monitoring is highly recommended in patients with cGvHD treated with immune suppressive drugs.
What should providers to keep in mind when making decisions on whether to prescribe a pediatric patient with JAK inhibitors?
It's important to make very careful selection of the patients and to monitor the safety profile and the efficacy of the drug. But certainly, in my personal view, ruxolitinib is a highly valuable therapeutic option in what can be defined as an unmet medical need. Now, pediatricians have a very important therapeutic options for treating these severe complications.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen